In a hemodialysis patient who is clinically stable with no signs of infection, is a pre‑dialysis vancomycin trough level of 14.9 mg/L acceptable given the target range of 15–25 mg/L?

A pre-HD vancomycin level of 14.9 mg/L is marginally acceptable in a clinically stable hemodialysis patient with no signs of active infection, though dose adjustment should be considered based on the clinical context.

Clinical Context Matters

In a stable patient without active infection, a trough of 14.9 mg/L (just 0.1 mg/L below target) is clinically reasonable and does not require immediate intervention. The 2009 IDSA/ASHP/SIDP guidelines specify that trough concentrations of 15-20 mg/L are recommended for serious infections such as bacteremia, endocarditis, osteomyelitis, meningitis, and hospital-acquired pneumonia caused by S. aureus 1. However, these targets were established for patients with normal renal function and serious active infections.

Key Considerations for HD Patients

The Challenge of Target Attainment

Recent evidence demonstrates that achieving and maintaining target vancomycin levels in HD patients is notoriously difficult:

• Only 45% of pre-dialysis concentrations fall within the 15-25 mg/L range in clinical practice, with 35% being subtherapeutic 2
• Target attainment rates can be as low as 16.7% during treatment courses 3
• The median target attainment across multiple centers shows significant variability 3

Clinical Stability Trumps Numerical Precision

For your stable patient without signs of infection, the 14.9 mg/L level represents adequate therapeutic coverage and does not warrant aggressive dose escalation. The guidelines emphasize that frequent monitoring for lower-intensity dosing (targeted to attain trough concentrations ≤15 mg/L) is not recommended 1.

Practical Management Algorithm

If Patient Remains Stable (No Fever, Improving Clinically):

• Accept the 14.9 mg/L level without immediate dose adjustment
• Continue current dosing regimen
• Recheck level before next dialysis session
• Monitor clinical response (fever curve, inflammatory markers, source control)

If Considering Dose Adjustment:

The decision depends on:

1. Interdialytic interval:

   • 48-hour interval: Consider small increase (5.9 mg/kg maintenance dose typically needed) 4
   • 72-hour interval: Higher doses required (7.1 mg/kg) due to longer time between sessions 4

2. Baseline level influence:

   • Since your level is 10-14.99 mg/L range, achieving 15-20 mg/L requires approximately 9.2 mg/kg (48h interval) or 10.0 mg/kg (72h interval) 4

3. Patient factors:

   • Residual urine output reduces target attainment (OR 0.48) 3
   • Age influences drug clearance 5

Important Caveats

Avoid Over-Treatment

• The risk of nephrotoxicity increases with sustained trough concentrations >20 mg/L 1, 6
• In HD patients, the clinical benefit of aggressive targeting to 15-20 mg/L for uncomplicated infections is not well-established 7
• One study found no difference in composite outcomes (mortality, clinical response, complications) between patients with and without trough level monitoring in HD patients with uncomplicated MRSA bacteremia 7

When Higher Levels ARE Critical

The 15-20 mg/L target becomes non-negotiable when:

• Active complicated infection (endocarditis, osteomyelitis, CNS infection)
• Documented MRSA with MIC approaching 1-2 mg/L
• Clinical deterioration or persistent bacteremia
• Inadequate source control

Bottom Line

For a stable HD patient without active infection signs, 14.9 mg/L is acceptable—you're splitting hairs at this level. Focus on clinical response rather than chasing a number that's 0.1 mg/L below an arbitrary cutoff. If the patient develops fever, hemodynamic instability, or other infection signs, then reassess dosing more aggressively. The evidence shows that achieving perfect target attainment in HD patients is extremely difficult 2, 3, 8, and clinical stability should guide your decision-making more than a single trough value that's marginally below target.